Details About Generic Salt ::  Palivizu

Main Medicine Class:: Monoclonal antibody   

(pal-eh-VIZ-u-mab)

Synagis

Class: Monoclonal antibody

 

Drugs Class ::

 Action Neutralizing and fusion-inhibitory activity ag!inst recpirator) syncytial virus (RSV), inhibiting RSV replication.

Indications for Drugs ::

 Indications Prevention of serious lower respiratory tract disease due to RSV in pediatric patients at high risk of RSV disease.

Drug Dose ::

 Route/Dosage

PEDIATRICS: IM 15 mg/kg, preferably in anterolateral aspect of thigh. Give doses > 1 ml in divided doses.

Contraindication ::

 Contraindications Standard considerations.

Drug Precautions ::

 Precautions

Pregnancy: Category C. Adults: Not indicated for adult use.

PATIENT CARE CONSIDERATIONS

Drug Side Effects ::

 Adverse Reactions

DERM: Rash. EENT: Otitis media; rhinitis; pharyngitis. HEPA: Increased AST. RESP: Upper respiratory tract infection. OTHER: Pain; hernia.

Drug Mode of Action ::  

 Action Neutralizing and fusion-inhibitory activity ag!inst recpirator) syncytial virus (RSV), inhibiting RSV replication.

Drug Interactions ::

 Interactions None well documented.

Drug Assesment ::

 Assessment/Interventions

• Obtain a complete health history, drug history, and history of allergies.
• Monitor patients at high risk for RSV disease such as pediatric patients with a history of bronchopulmonary dysplasia (BPD) or prematurity.
• Have epinephrine (1:1000) available for immediate use if anaphylaxis or severe allergic reaction occurs.
• Monitor patient for adverse reactions including erythema, vomiting, diarrhea, injection site induration, or inflammation.

Drug Storage/Management ::

 Administration/Storage

• Store in original container between 2° and 8° C (35.6° and 46.4°F). Do not freeze.
• Reconstitute by first removing the tab portion of the vial cap and cleaning the rubber stopper with 70% ethanol or equivalent. Slowly add 1 ml of Sterile Water for Injection to a 100 mg vial. Gently swirl the vial for 30 sec to avoid foaming. Do not shake vial. After reconstitution let stand at room temperature for a minimum of 20 min until the solution clarifies.
• Follow strict aseptic technique. Use disposable syringes and needles; do not reuse syringes or needles.
• Do not use the gluteal muscle because of risk of damage to the sciatic nerve.
• Administer within 6 hr after reconstitution as palivizumab does not contain a preservative.
• Administer with caution to a patient with thrombocytopenia or any other bleeding or coagulation disorder.

Drug Notes ::

 Patient/Family Education

• Instruct family that palivizumab is given for the prevention of serious lower respiratory tract disease caused by RSV in pediatric patients at high risk for complications of RSV infections.
• Instruct parent or family that the child should receive a monthly palivizumab dose throughout the RSV season to maintain a protective level of antibodies against the virus in the blood.
• Instruct parent or family concerning other nonpharmacological methods of infection prevention (ie, preventing exposure to secondhand cigarette smoke and other environmental dangers) and ensuring adequate hydration and rest, humidified air, and proper ventilation.
• Instruct family to report any adverse events that include, but are not limited to, upper respiratory infections, signs and symptoms of otitis media (eg, ear tugging, tenderness), fever, rhinitis, rash, sore throat, or hoarseness immediately to their primary caregiver.

Disclaimer ::

The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.